Updated: Roivant’s FcRn antibody for autoimmune disease shows early potential in study with healthy subjects
Roivant Sciences’ Immunovant has unveiled biomarker results for its autoimmune disease antibody drug from a Phase I healthy subject trial.
The subcutaneous drug, dubbed IMVT-1402, targets the neonatal fragment crystallizable receptor (FcRn) for immunoglobulin G (IgG)-mediated autoimmune diseases.
Immunovant’s stock price $IMVT soared by 87% to about $38.00 on Tuesday in response to the data, while Roivant $ROIV — which owns a controlling share of Immunovant — went up by 23% to $12.60.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.